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Abstract: We hypothesized that bronchodilator treatment not only improves hyperinflation and 
endurance capacity but also muscular efficiency in stable chronic obstructive pulmonary disease 
(COPD). We aimed to demonstrate that tiotropium and salmeterol improve muscular efficiency 
compared with placebo. Twenty-five COPD patients were studied, including 20 males of mean 
(standard deviation) age 62 years (7 years) with baseline forced expiratory volume in 1 second of 
41% (10%) predicted, and maximal workload of 101 Watt (36 Watt). Subjects were randomized for 
6-week treatment with tiotropium 18 µg once daily, salmeterol 50 µg twice daily, or placebo using 
a double-blind, crossover design. Muscular efficiency and endurance time were measured during 
cycling at 50% of maximal work load. Resting energy expenditure was measured using a ventilated 
hood. Muscular efficiency after tiotropium, salmeterol, and placebo treatment was 14.6%, 14.4%, 
and 14.4%, respectively (P  0.05), and resting energy expenditure was 1485 kcal/24 hours, 
1709 kcal/24 hours, and 1472 kcal/24 hours (P  0.05), respectively. Endurance time after 
tiotropium treatment was significantly higher than that after placebo (27.0 minutes versus 
19.3 minutes [P = 0.02]), whereas endurance time after salmeterol treatment was not higher than 
that after placebo (23.3 minutes [P = 0.22]). In this small study, we were not able to demonstrate 
that bronchodilator therapy improved muscular efficiency. Apparently, reduced costs of breathing 
relative to total energy expenditure were too small to be detected. 
Keywords: bronchodilation, chronic obstructive pulmonary disease, energy expenditure, muscle 
energetics, muscular exercise
Introduction
Patients with chronic obstructive pulmonary disease (COPD) often have impaired 
exercise tolerance, leading to reduced physical activity and low quality of life. 
Impaired exercise tolerance is due to a complex interplay between limitations in 
ventilatory capacity, gas exchange, cardiovascular capacity, and peripheral muscle 
metabolism. Static and dynamic hyperinflation during exercise plays an important 
role and may initiate a vicious circle of decline that includes physical deconditioning 
and worsening of dyspnea.1 Lung deflation by means of bronchodilators reduces 
hyperinflation and improves submaximal exercise endurance, as was shown for 
both the long-acting-β-2 agonist salmeterol and the long-acting anticholinergic 
agent tiotropium.2,3 One study demonstrated that both agents were equally effective 
at improving functional residual capacity (FRC) and inspiratory capacity (IC) at rest 
and at increased breathing frequencies (15 breaths/minute, 30 breaths/minute, and 
45 breaths/minute).4 No published direct comparison between the two agents’ effect 
on submaximal exercise tolerance exists.International Journal of COPD 2011:6
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Figure 1 The six possible treatment sequences to which patients were randomly 
assigned. There was no washout period between successive treatment sequences.
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Energy expenditure at a constant submaximal workload is 
another way to investigate hyperinflation and its consequences 
for exercise tolerance. “Muscular efficiency” of movement 
is frequently used to express the efficacy of skeletal 
muscles to transfer biochemical energy into external work 
or movement.5 Calculations of muscular efficiency during 
steady-state situations are based on open-circuit indirect 
calorimetry (oxygen uptake [VO2], carbon dioxide output 
[VCO2]) and the assumption that energy requirements in the 
muscles are met by respiration. Baarends et al6 showed that 
after correction for resting energy expenditure (REE), the net 
muscular efficiency in 33 patients with mild-to-moderately 
severe COPD ranged from 8.5% to 22.7% (median 15.5%). 
Interestingly, patients with a low net muscular efficiency 
(,17%) demonstrated enhanced ventilatory responses to 
exercise and higher airway resistance at rest. This suggests 
that decreased muscular efficiency is related to increased 
costs of breathing, probably due to hyperinflation.
We speculated that measurement of muscular efficiency in 
COPD can detect improvements in costs of breathing induced by 
tiotropium or salmeterol. We hypothesized that both treatments 
improve muscular efficiency, along with endurance capacity, 
in clinically stable patients with COPD who demonstrated 
ventilatory limitation during maximal exercise.
Methods
Patients
Outpatients with stable COPD were recruited from 
pulmonary departments of hospitals in the north of The 
Netherlands. Patients had to be $40 years old with a 
diagnosis of moderate-to-severe COPD (forced expiratory 
volume in 1 second [FEV1] # 60% predicted; FEV1/forced 
vital capacity [FVC] # 70%) and a smoking history of 10 
pack-years. FEV1% predicted had to increase by 5% after 
inhalation with 480 µg salbutamol and 80 µg ipratropium 
(Combivent®, Boehringer Ingelheim, Ridgefield, CT, 
USA). The use of inhaled and oral steroids (maximally 
10 mg a day) was allowed during the study. Patients who 
needed supplemental oxygen and who had three or more 
exacerbations per year were excluded. Ventilatory limitation 
of maximal exercise capacity was required (defined by an 
increase in oxygen tension in arterial blood [PaCO2] and/or 
an increase in minute ventilation [VE]  80% [FEV1 × 37.5]). 
Additionally, patients required a maximal workload (Wmax) 
of $40 Watt during an incremental cycle test. The main 
exclusion criteria for the study included a 10 mmol/L increase 
in blood lactate during peak exercise or 2.5 mmol/L at $50% 
of Wmax and oxygen saturation ,90% at 50% of Wmax.
study design
This was a randomized, double-blind, double-dummy, 
placebo-controlled, crossover study, conducted over three 
6-week periods. The effects of tiotropium, salmeterol, 
and placebo on muscular efficiency were compared. The 
primary endpoint was change in gross muscular efficiency 
following 6 weeks of randomized treatment. Secondary 
endpoints included REE, endurance capacity at 50% Wmax, 
net muscular efficiency, FEV1, FVC, peak expiratory flow 
(PEF) variability over 1 week, specific airway conductance 
(sGaw), FRC, and symptoms determined using the Clinical 
COPD Questionnaire (CCQ). The study was approved by the 
local independent ethics committee, and informed consent 
was obtained from all individuals.
study protocol
Following screening and a 4-week run-in period, 25 patients 
were randomized to one of six treatment sequences (Figure 1). 
During each 6-week treatment period, patients received either 
tiotropium 18 µg once daily, salmeterol 50 µg twice daily, or 
placebo twice daily. Salbutamol was taken as required, using a 
metered dose inhaler, but not during the 8 hours prior to testing. 
Testing occurred after each 6-week period between 8 a.m. and 
10 a.m., 1 hour after drug administration. Visits were delayed 
for maximally 2 weeks in case of an exacerbation. PEF was 
measured twice daily during the 6-week periods.
Incremental bicycle ergometer test
Maximal exercise capacity was measured using an incremental 
symptom-limited cycle ergometer test. Patients inhaled 
four puffs of ipratropium/salbutamol 20/120 µg (Combivent) 
via an AeroChamber® (Boehringer Ingelheim, Ingelheim, 
Germany) 30 minutes before commencing the test. A brachial 
or radial artery catheter was inserted, and samples were drawn 
at rest and then every 2 minutes. VE, VO2, and VCO2 were International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
231
Bronchodilation and muscular efficiency in COPD
measured from breath-by-breath analysis every 30 seconds 
(EOS Sprint; Jaeger, Würzburg, Germany). Dyspnea was 
assessed every minute using a modified Borg scale.7
The test required 2 minutes of seated rest on the ergometer 
when baseline measurements were collected. Patients were 
then instructed to pedal at 60–70 revs/minute. After 5 minutes, 
unloaded cycling power was increased every minute by 
work rate of 10% of the estimated Wmax (according to the 
European Respiratory Society criteria), until the patient 
was unable to maintain the pedaling frequency. Reasons 
for stopping were recorded. Peak values were the average 
over the last 20 seconds of the maximum completed work. 
Peak VO2 was predicted using equations for healthy subjects 
older than 55 years of age.8 Peak VE was predicted from the 
Carter et al’s9 equation: 37.5 × FEV1.
Muscular efficiency and REE
Gross muscular efficiency (%) was assessed by measuring 
energy expenditure (EE) during cycling at 50% of Wmax. 
Immediately after reaching steady state, EE was averaged 
over a period of at least 5 minutes. In addition, steady-state 
EE was measured at isotime, a time point that was determined 
by the shortest exercise time of each subject. After reaching 
the constant workload of 50% Wmax, patients were asked 
to continue cycling for as long as possible. Gross muscular 
efficiency (%) was calculated using the equation load (Watt) 
of exercise × 0.01433 kcal/min/EE kcal/min × 100%. REE 
was measured using an open-circuit indirect calorimetry 
system using a ventilated hood (Oxycon Beta®, Jaeger). 
Measurements were taken in the early morning, following 
an overnight fast, with patients in a supine position. Net 
muscular efficiency (%) was calculated using the values 
obtained for the gross muscular efficiency and REE using 
the equation10 load (W) of exercise × 0.01433 kcal/min/
EE - REE kcal/min × 100%. In a pilot study, mean (standard 
deviation [SD]) differences of two measurements (interval 
of 1–2 weeks) of gross muscular efficiency, net muscular 
efficiency, and REE were 0.011% (0.82%), 0.035% (1.76%), 
and 7 kcal/24 hours (228 kcal/24 hours).
Lung function
Lung function tests were performed according to the guidelines 
of the European Respiratory Society11 and included FEV1 and 
FVC. Screening FEV1 was measured before and 40 minutes 
after 480 µg salbutamol and 80 µg ipratropium (Combivent). 
Total lung capacity, FRC, airway resistance, and sGaw were 
measured by body plethysmography (Masterlab®, Jaeger 
Würzburg, Germany). PEF values (MiniWright®,  Clement 
Clarke International, Harlow, UK) were recorded twice daily 
during the treatment periods, immediately after waking up and 
just before going to sleep, and always before study medication. 
PEF day-to-day variability was defined by (highest morning 
PEF - highest morning PEF of the day before) × 100%, 
averaged over 7 successive days. PEF within-day variability 
was defined by (highest PEF - lowest PEF)/(mean value 
of 2) × 100%, averaged over 7 successive days.
Disease-specific symptoms were assessed using the 
CCQ. This is a self-administered questionnaire specifically 
developed to measure clinical control in patients with 
COPD.12 CCQ score ,1 = no limitation, $1 and ,2 = mild 
limitation, $2 and ,3 = moderate limitation, and $3 = severe 
limitation. Adverse events occurring during the study period 
were monitored and recorded.
statistical analysis
Statistics were computed using SAS® Version 8.02 (SAS 
Institute Inc., Cary, NC, USA). Characteristics of the study 
group are given as mean (SD). Statistical analysis was 
performed using a full analysis set and analysis of variance. 
Twenty-four patients were required in order to detect an 
absolute difference of 1% in mean gross muscular efficiency 
between the two treatments at the 5% significance level with 
90% power. P , 0.05 was considered significant.
Results
Patients had moderate-to-severe COPD (Table 1). Four patients 
had an exacerbation during the study. One exacerbation led 
to discontinuation of the study. No hospitalizations occurred 
during the study period.
Of the 25 patients randomized, 23 received tiotropium, 
24 salmeterol, and 24 placebo. Both tiotropium and 
salmeterol improved FEV1, FVC, FRC, and sGaw compared 
with placebo (Table 2). Differences between tiotropium and 
salmeterol were not statistically significant.
Compared with placebo, neither tiotropium nor sal-
meterol significantly improved the primary endpoint of 
mean gross muscular efficiency after 6 weeks of   treatment 
(Table 3). Active treatment did not significantly changed 
mean net muscular efficiency, VO2, VCO2, VE, and 
tidal volume. Mean (SD) REE values after tiotropium, 
  salmeterol, and placebo treatment were 1485 kcal/24 hours 
(112 kcal/24 hours), 1709 kcal/24 hours (105 kcal/24 hours), 
and 1472 kcal/24 hours (120 kcal/24 hours), respectively.
 Irrespective of the absence of change in the primary 
outcome, a significant improvement above placebo in exercise 
endurance was observed after 6 weeks with tiotropium but International Journal of COPD 2011:6
Table 1 screening characteristics (n = 25)a
Screening characteristics N (mean [SD])
Clinical characteristics
Age (years) 62.0 (7.1)
sex (% males) 20 (80)
smoking history (pack-years) 45.3 (26.9)
Current smoker/exsmoker (%) 40/60
number of corticosteroid users, inhaled/oral 19/2
Duration of COPD (years) 7.4 (5.9)
Body mass index (kg/m2) 24.6 (3.4)
Prebronchodilator FeV1 (% predicted) 40.7 (10.4)
Postbronchodilator FeV1 (% predicted) 48.1 (10.1)
FeV1/FVC × 100 (%) 39.1 (8.8)
FVC (% predicted) 3.9 (0.7)
Maximal incremental bicycle test
Maximal workload (Watt) 99.6 (37.2)
VO2 at maximum (L/minute) 1128.9 (394.7)
  PaO2 at rest (mmhg) 50.6 (198.4)
  PaO2 at maximum (mmhg) 54.5 (181.5)
  PaCO2 at rest (mmhg) 25.0 (96.3)
  PaCO2 at maximum (mmhg) 34.5 (115.3)
  Lactate rest (mmol/L) 1.5 (1.2)
  Lactate at maximum (mmol/L) 6.5 (2.5)
subjective reason for stopping exercise
  Discomfort with legs (%) 2 (8)
  Discomfort with breathing (%) 19 (76)
  Both discomfort with legs and breathing (%) 3 (12)
  Pain in the chest (%) 0 (0)
  Other (%) 1 (4)
Dyspnea Borg before exercise 0.2 (0.4)
Dyspnea Borg at end of exercise 7.0 (1.9)
Note: aValues are means (sD) or numbers (% proportion).
Abbreviations:  BMI,  body  mass  index;  CO2,  carbon  dioxide;  COPD,  chronic 
obstructive  pulmonary  disease;  FeV1,  forced  expiratory  volume  in  1  second; 
FVC, forced vital capacity; O2, oxygen; sD, standard deviation; VO2, oxygen uptake.
Table 3 Constant-load exercise after 6 weeks of treatmenta
Tiotropium Salmeterol Placebo
Immediately after reaching steady state
gross muscular  
efficiency (%)
13.01 (0.32)* 13.17 (0.30)* 14.14 (0.34)
net muscular  
efficiency (%)
16.03 (0.57) 17.15 (0.51) 17.12 (0.65)
ee (Kcal/min) 5.43 (0.24) 5.32 (0.22) 5.40 (0.25)
VO2 (mL/min) 1018.05 (18.22) 1019.30 (17.38) 1015.51 (19.59)
VCO2 (mL/min) 897.65 (13.80) 898.20 (13.16) 888.32 (14.84)
At isotime (shortest exercise time)
gross muscular  
efficiency (%)
14.55 (0.31) 14.35 (0.30) 14.42 (0.33)
net muscular  
efficiency (%)
19.34 (0.54) 18.51 (0.51) 19.07 (0.62)
ee (Kcal/min) 5.02 (0.10) 5.07 (0.09) 5.01 (0.10)
VO2 (mL/min) 1026.30 (20.72) 1037.91 (19.75) 1026.18 (21.96)
VCO2 (mL/min) 898.40 (15.83) 904.32 (15.08) 893.35 (16.77)
Notes: aValues are means (standard error); *P , 0.05 versus placebo; **P , 0.01 
versus placebo; ***P , 0.001 versus placebo.
Abbreviations:  ee,  energy  expenditure;  VCO2,  carbon  dioxide  production; 
VO2, oxygen consumption.
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Discussion
This study investigated the effects of two long-acting 
bronchodilators on working energy expenditure and REE in 
COPD. The mean gross muscular efficiency and REE did not 
differ significantly from placebo with either tiotropium or 
salmeterol treatment. Only tiotropium significantly improved 
exercise endurance. Consistent with the results of other studies, 
not with salmeterol (Figure 2). After 6 weeks, mean (SD) 
endurance time was 26.96 minutes (2.26 minutes) with 
tiotropium compared with 19.30 minutes (2.34 minutes) with 
placebo (P = 0.02). Mean (SD) endurance time after salmeterol 
was 23.33 minutes (2.26 minutes) (P = 0.22 versus placebo).
No correlations were present between changes in endurance 
time and FEV1, FRC, or gross muscular efficiency.
Assessment of patients’ symptoms and functional state by 
total CCQ scores suggested a significant reduction with both 
tiotropium (P = 0.011) and salmeterol (P = 0.0003) (Figure 3, 
Table 4). This was mainly due to significant changes in the 
symptoms and functional state domains. Differences between 
tiotropium and salmeterol were not statistically significant 
(P = 0.20).
Weekly mean (SD) number of puffs of rescue medication 
over the last 3 weeks on treatment were 11.9 (18.5), 12.0 
(17.2), and 15.5 (18.5) for tiotropium, salmeterol, and 
placebo, respectively.
Table 2 Pulmonary function values after 6 weeks of treatmenta
Function Tiotropium Salmeterol Placebo
FeV1 (L) 1.32 (0.03)* 1.27 (0.03)** 1.14 (0.03)
FVC (L) 3.27 (0.06)* 3.12 (0.06)* 2.81 (0.06)
FeV1/FVC (%) 40.70 (0.7) 40.81 (0.7) 41.20 (0.73)
TLC (L) 7.72 (0.09)*** 7.85 (0.09)** 8.13 (0.09)
rV (L)1 3.97 (0.10)* 4.37 (0.10)*** 4.90 (0.11)
FrC (L) 5.13 (0.12)** 5.13 (0.12)** 5.61 (0.13)
raw (kPa sec/L) 0.49 (0.03)* 0.54 (0.03)*** 0.68 (0.03)
sgaw 1/(kPa sec) 0.51 (0.03)* 0.45 (0.03)* 0.31 (0.03)
Diary data
Morning PeFb  
(L/min)
248.91 (3.63)* 250.24 (3.52)* 229.98 (3.63)
evening PeF  
(L/min)
260.24 (3.26)* 253.63 (3.14)* 231.91 (3.26)
Day-to-day PeF  
variability
5.55 (0.53) 5.45 (0.53) 6.72 (0.56)
Within-day  
PeF variability
11.25 (1.40) 7.91 (1.34) 10.92 (1.44)
Notes: aValues are means (standard deviation [sD]) adjusted for patient and cycle 
using analysis of covariance;  bPeF values were assessed in the 6-week treatment 
periods,  whereas  the  other  lung  functions  were  assessed  1  hour  after  drug 
administration and 1 hour in advance of the submaximal bicycle tests; *P , 0.001 
versus placebo; **P , 0.05 versus placebo; ***P , 0.01 versus placebo.
Abbreviations: FeV1, forced expiratory volume in 1 second; FrC, functional residual 
capacity; FVC, forced vital capacity; PEF, peak expiratory flow; Raw, airway resistance; 
RV, residual volume; sGaw, specific airway conductance; TLC, total lung capacity.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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both drugs significantly improved symptoms, functional state, 
and lung function, including parameters of hyperinflation.
Cost of breathing during maximal exercise may rise 
to 35%–40% of the maximal oxygen consumption and 
contribute significantly to the limited physical performance of 
patients with COPD.13 Assuming that effective bronchodilator 
therapy reduces the work of breathing during submaximal 
cycling by 25%, total energy expenditure during exercise 
would be anticipated to be reduced by 8%–10%. This 
study was statistically powered to detect a change in gross 
muscular efficiency of 1%, which reflects a relative change of 
approximately 7%. With a sample size of 24 subjects, we feel 
95% confident that both salmeterol and tiotropium improved 
total energy expenditure by no more than 7%. Our results 
are in line with a study investigating the effects of pressure 
support ventilation in severe COPD patients who cycled at a 
mean constant work load of 33 Watts.14 Despite significantly 
improved VE and inspiratory effort, no changes were found 
in oxygen consumption. The authors concluded that the 
anticipated reduction in oxygen cost of breathing relative to 
total oxygen consumption was too small to be detected.
Recently, the underlying mechanisms of decreased 
muscular efficiency in COPD have been examined and may 
explain, at least in part, our findings. Arterial and venous blood 
flow in the legs during a two-leg cycle exercise and single 
knee-extensor exercise was compared between COPD patients 
and age-matched healthy controls.15 At a given workload, local 
oxygen consumption in leg muscles was significantly higher in 
COPD patients than in healthy controls. In addition, a higher 
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Figure 2 endurance time at 50% maximal workload after 6 weeks of treatment.
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Figure 3 Clinical COPD Questionnaire after 6 weeks of treatment.
Table 4 Clinical COPD Questionnaire items after 6 weeks of 
treatmenta
Tiotropium Salmeterol Placebo
Symptom domain
short of breath at rest 0.69 (0.18)* 0.47 (0.18)* 1.69 (0.18)
short of breath during  
physical exercise
2.63 (0.21)** 2.18 (0.21)* 3.67 (0.22)
Did you cough? 1.77 (0.19) 1.69 (0.19) 2.02 (0.20)
Did you produce phlegm? 1.59 (0.21) 1.32 (0.21) 1.76 (0.22)
Mental state domain
Concerned about getting  
a cold/exacerbation
0.50 (0.14) 0.28 (0.14) 0.65 (0.15)
Depressed due to  
breathing problems
0.68 (0.19) 0.65 (0.19) 0.92 (0.19)
Functional state domain
Daily activities at home 1.10 (0.21) 0.73 (0.21)** 1.53 (0.21)
social activities 0.77 (0.20) 0.64 (0.20) 1.21 (0.21)
Moderate physical activities 2.54 (0.24)*** 2.09 (0.24)** 3.27 (0.25)
strenuous physical exercises 1.59 (0.22) 1.24 (0.22)** 2.22 (0.23)
Notes:  aValues are means (standard error) adjusted for patient and cycle using 
analysis  of  covariance;  *P  ,  0.001  versus  placebo;  **P  ,  0.01  versus  placebo; 
***P , 0.05 versus placebo.International Journal of COPD 2011:6 submit your manuscript | www.dovepress.com
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in patients with a cardiovascular limitation or oxygen uptake 
disorder. However, muscular efficiency was tested at 50% of 
Wmax, at which breathing frequency may have been too low to 
significantly increase hyperinflation and the work of breathing. 
Finally, we excluded subjects with oxygen desaturation and/or 
lactate production at 50% of Wmax, as energy release due to 
anaerobic combustion is not measured by indirect calorimetry. 
However, arterial blood samples may not reflect local anaerobic 
combustion in the leg and respiratory muscles.
Net muscular efficiency in our study was somewhat higher 
than the 15.5% (8.5%–22.7%) values of Baarends et al.6 Their 
study took place in a pulmonary rehabilitation center and 
included COPD patients with similar age (61 years) and 
FEV1 (37% predicted), yet with a lower Wmax (58 Watt). 
Muscular efficiency in their study was measured during 
submaximal cycling at a work load of (on average) 30 Watt 
versus (on average) 50 Watt in our study, suggesting that the 
lower values of net muscular efficiency reported by Baarends 
et al6 reflect methodological differences and more severe 
disease. Interestingly, Perrault et al27 demonstrated similar 
delta muscular efficiency in COPD patients (FEV1 36% 
predicted) and age-matched controls; however, COPD 
patients and controls did not cycle at the same workloads. To 
our knowledge, no studies compared net muscular efficiency 
of COPD patients and age-matched healthy controls during 
cycling at similar workloads.
We hypothesized that salmeterol would increase REE and 
therefore decrease gross muscular efficiency. This was based 
on the finding of a 5% increase in REE after inhaling 5 mg 
salbutamol in patients with COPD.28 Another study showed a 
positive correlation between 24-hour total energy expenditure 
and the daily dose of inhaled β-2-agonists.29 Such findings 
have not been demonstrated for the anticholinergic drug 
ipratropium bromide.30 Our nonsignificant finding (P = 0.15 
for salmeterol versus placebo) may be due to insufficient 
statistical power or may reflect adaptation in resting 
metabolism after 6-week treatment with salmeterol.
Conclusion
We conclude that muscular efficiency and REE do not 
improve after 6-week treatment with tiotropium or salmeterol 
in clinically stable COPD. This lack of effect occurs despite 
significant improvements in lung function, including parameters 
of hyperinflation, and, in cases of tiotropium treatment only, 
significant improvements in exercise endurance. We assume 
that the reduced costs of breathing relative to total energy 
expenditure were too small to be detected. Future studies should 
focus on the effects of bronchodilators on cardiovascular and 
local leg performance during submaximal exercise.
proportion of type II muscle fibers in the vastus lateralis muscle 
from COPD patients suggested that the reduced muscular 
efficiency of the leg muscles was due to the contribution of 
less effective muscle fibers. In contrast, respiratory muscles 
in COPD are suggested to have an elevated proportion of very 
efficient type I fibers.16 This suggests that, in exercising COPD 
patients, the contribution of peripheral muscle dysfunction to 
pathologically increased total energy expenditure might be 
more important than the increased work of breathing.
Tiotropium significantly improved airway conductance 
(±60%) and FRC (±9%) as well as endurance time (±40%), 
yet without significant correlations between these parameters. 
Other studies demonstrated modest correlations between 
changes in endurance capacity and changes in FEV1 or IC 
induced by ipratropium17 and tiotropium,18 whereas 20% of 
patients failed to improve endurance time despite positive 
effects on lung function.17 Consequently, bronchodilators 
may alter rate-limiting factors other than lung function. In 
this respect, a rate-limiting blood flow has been demonstrated 
in the lower limbs of some COPD patients during cycling 
exercise.19 In healthy subjects, a local reflex vasoconstriction 
due to the increased work of breathing has been suggested 
to reduce leg blood flow and to promote quadricep fatigue 
during cycling at relatively high work loads.20,21 Unloading 
of the respiratory muscles improved time to exhaustion 
and exercise-induced quadricep muscle fatigue.20–23 Similar 
mechanisms may have improved the endurance time in 
our tiotropium-treated COPD patients. Redistribution of 
blood to the legs after tiotropium inhalation may also be the 
result of an improved cardiac performance. Travers et al24 
demonstrated that heart rate was lower with tiotropium at 
rest and during exercise, with a corresponding increase in 
oxygen pulse (surrogate measure of cardiac stroke volume) 
and decrease in the rate pressure product (surrogate measure 
of myocardial work). Together, these findings give rise to 
a new research question: is tiotropium-improved endurance 
capacity in COPD the consequence of reduced hyperinflation 
as well as increased leg blood flow?
We anticipated that patients with modest reversibility after 
Combivent would improve notably, as one study demonstrated 
that work of breathing improved by 25% after inhaling 
a single dose of formoterol in COPD patients with a mean 
reversibility in FEV1 of 5% predicted.25 Retrospectively, it 
may have been better to have selected patients on the basis 
of volume (hyperinflation) instead of flow (FEV1) response, 
although both frequently occur together.26 Additionally, we 
selected COPD patients with a proven ventilatory limitation 
at maximal work load, assuming that reduced muscular 
efficiency due to dynamic hyperinflation is more common International Journal of COPD
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